Clinical Trial Update: An Observational Study of RoActemra/Actemra in Patients With Moderate to Severe Rheumatoid Arthritis

View source ↗

Summary

An observational study of RoActemra/Actemra (tocilizumab) in patients with moderate to severe rheumatoid arthritis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• RoActemra/Actemra (tocilizumab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Rheumatoid Arthritis | Status: COMPLETED